

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Narmada SHENOY et al.

Title: FORMULATIONS FOR PHARMACEUTICAL AGENTS IONIZABLE AS
FREE ACIDS OR FREE BASES

Appl. No.: 09/716,332

Filing Date: 11/21/2000

Examiner: Unassigned

Art Unit: 1615

RECEIVED
TECH CENTER 1600/2900
01 AUG 31 AM 9:10

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
Box PATENT APPLICATION
Washington, D.C. 20231

Sir:

Submitted herewith on Form PTO-1449 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56. A copy of each listed document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits, and within three (3) months of the mailing date of the foreign search report.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

References A11- A13, A33, A36 and A43-A47 were all cited in the corresponding International Search Report. A copy is attached for your convenience. The remaining references were cited in related patents and/or co-pending related applications.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO-1449 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date August 30, 2001

FOLEY & LARDNER
Washington Harbour
3000 K Street, N.W., Suite 500
Washington, D.C. 20007-5109
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

By Mary C. Gill Reg. #41,545
for Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 038602/1060	SERIAL NO.: 09/716,332
INFORMATION DISCLOSURE CITATION		APPLICANT: Namada SHENOY, et al.	
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	A1	4,002,749	01-11-77	Rovnyak et al.	424	246	08-12-75
	A2	4,053,613	10-11-77	Rovnyak et al.	424	246	09-17-75
	A3	4,966,849	10-30-90	Vallee et al.	435	199	2-2-89
	A4	5,217,999	06-08-93	Levitzki et al.	514	613	3-24-92
	A5	5,302,606	04-12-94	Spada et al.	514	357	4-16-91
	A6	5,330,992	07-19-94	Eissenstat et al.	514	312	10-23-92
	A7	5,786,488	07-28-98	Tang et al.	548	455	11-5-97
	A8	5,792,783	08-11-98	Tang et al.	514	397	6-5-96
	A9	5,840,745	11-24-98	Buzzetti et al.	514	414	12-22-95
	A10	5,880,141	03-09-99	Tang et al.	514	339	6-7-95
	A11	5,883,113	03-16-99	Tang et al.	514	418	6-5-96
	A12	5,883,116	03-16-99	Tang et al.	514	418	6-5-98
	A13	5,886,020	03-23-99	Tang et al.	514	418	6-5-96
	A14	Re 36,256	07-20-99	Spada et al.	514	249	12-10-97

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES/NO
	A15	91/13055	09-05-91	WO			
	A16	91/15495	10-17-91	WO			
	A17	92/07830	05-14-92	WO			
	A18	92/20642	11-26-92	WO			
	A19	92/21660	12-10-92	WO			
	A20	93/01182	01-21-93	WO			
	A21	93/23040	11-25-93	WO			
	A22	94/03427	02-17-94	WO			
	A23	94/10202	05-11-94	WO			
	A24	94/14808	07-07-94	WO			
	A25	95/01349	01-12-95	WO			
	A26	95/14667	06-01-95	WO			
	A27	95/24190	09-14-95	WO			
	A28	96/00226	01-04-96	WO			
	A29	96/16964	06-06-96	WO			
	A30	96/22976	08-01-96	WO			
	A31	96/32380	10-17-96	WO			
	A32	96/40116	12-19-96	WO			

RECEIVED
TECH CENTER
1600/2900
01 AUG 31 AM 9:21

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 038602/1060	SERIAL NO. : 09/716,332				
INFORMATION DISCLOSURE CITATION		APPLICANT: Narmada SHENOY, et al.					
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615				
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES/NO
	A33	98/07695	02-26-98	WO			
	A34	98/07835	02-26-98	WO			
	A35	98/24432	06-11-98	WO			
	A36	98/38984	09-11-98	WO			
	A37	98/45708	10-15-98	WO			
	A38	98/50356	11-12-98	WO			
	A39	98/56376	12-17-98	WO			
	A40	99/10325	03-04-99	WO			
	A41	99/19325	4-22-99	WO			
	A42	99/48868	09-30-99	WO			
	A43	99/61422	12-02-99	WO			
	A44	00/56709	09-28-00	WO			
	A45	00/38519	07-06-00	WO			
	A46	00/35908	06-22-00	WO			
	A47	00/08202	02-17-00	WO			
	A48	0 252 731 A2	01-13-88	EP			
	A49	0 304 493	03-01-89	EP			
	A50	0 566 226 A1	10-20-93	EP			
	A51	0 934 931 A2	08-11-99	EP			
	A52	0 934 931 A3	08-11-99	EP			
	A53	1 599 772	07-20-70	France			
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
	A54		Akbasak and Sunar-Akbasak., "Oncogenes: cause or consequence in the development of glial tumors," <u>J. Neurol. Sci.</u> 111:119-133 (1992)				
	A55		Andreani et al., "Synthesis and potential <i>coanthracyclinic</i> activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones," <u>Eur. J. Med. Chem.</u> 32:919-924 (1997) ©Elsevier, Paris.				
	A56		Andreani et al., "In vivo cardiotoxic activity of pyridylmethylene-2-indolinones" <u>Arzneimittel-Forschung Drug Research</u> 48(II): 727-729 (1998)				
	A57		Andreani et al., "Synthesis and cardiotoxic activity of 2-indolinones," <u>Eur. J. Med. Chem.</u> 25(2):187-190 (1990).				
	A58		Arteaga et al., "Blockade of the Type I Somatomedin Receptor Inhibits Growth of Human Breast Cancer Cells in Athymic Mice," <u>J. Clin. Invest.</u> 84:1418-1423 (1989) ©The American Society for Clinical Investigation, Inc.				
	A59		Arvidsson et al., "Try-716 in the Platelet-Derived-Growth-Factor β -Receptor Kinase Insert is Involved in GRB2 Binding and Ras Activation," <u>Molecular and Cellular Biology</u> 14(10):6715-6726 (1994) ©The American Society for Microbiology				

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 038602/1060	SERIAL NO. : 09/716,332
		APPLICANT: Narmada SHENOY, et al.	
INFORMATION DISCLOSURE CITATION			
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)			
	A60	Baserga, "Oncogenes and the Strategy of Growth Factors," <u>Cell</u> 79:927-93 (1994) ©Cell Press	
	A61	Baserga, "The Insulin-like Growth Factor I Receptor: A Key to Tumor Growth?" <u>Cancer Research</u> 55:249-252 (1995)	
	A62	Bolen et al., "The Src family of tyrosine protein kinases in hemopoietic signal transduction," <u>FASEB J.</u> 6:3403-3409 (1992)	
	A63	Bolen, "Nonreceptor tyrosine protein kinases," <u>Oncogene</u> 8:2025-2031 (1993) ©MacMillan Press Ltd.	
	A64	Bonner et al., "Structure and Biological Activity of Human Homologs of a raf-mil Oncogene," <u>Molecular and Cellular Biology</u> 5:1400-1407 (1985) ©The American Society for Microbiology	
	A65	Cance et al., "Novel Protein Kinases Expressed in Human Breast Cancer," <u>Int. J. Cancer</u> 54:571-577 (1993) ©Wiley-Liss, Inc.	
	A66	Carpenedo et al., "Identification and Measurement of Oxindole (2-Indolinone) in the Mammalian Brain and Other Rat Organs" <u>Analytical Biochemistry</u> 244:74-79 (1997) ©Academic Press, Inc.	
	A67	Chen et al., "Effects of 3,3-Dipyridylmethyl-1-Phenyl-2-Indolinone on γ -Aminobutyric Acid Elicited Chloride Current of Snail Central Neuron" <u>Chinese Journal of Physiology</u> 40(3):149-156 (1997)	
	A68	Claesson-Welsh, "Signal Transduction by the PDGF Receptor," <u>Progress in Growth Factor Research</u> 5:37-54 (1994) ©Elsevier Science Ltd.	
	A69	Coppola et al., "A Functional Insulin-Like Growth Factor I Receptor is Required for the Mitogenic and Transforming Activities of the Epidermal Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 14:4588-4595 (1994) ©The American Society for Microbiology	
	A70	Damiani et al., "Inhibition of Copper-Mediated Low Density Lipoprotein Peroxidation by Quinoline and Indolinone Nitroxide Radicals," <u>Biochemical Pharmacology</u> 48(6):1155-1161 (1994) ©Elsevier Science Ltd.	
	A71	Davis et al., "Synthesis and microbiological properties of 3-Amino-1-Hydroxy-2-Indolinone and Related Compounds," <u>Journal of Medicinal Chemistry</u> 16(9):1043-1045 (1973) ©American Chemical Society	
	A72	De Vries et al., "The <i>fms</i> -Like Tyrosine Kinase, a Receptor for Vascular Endothelial Growth Factor," <u>Science</u> 255:989-991	
	A73	Decker and Lohmann-Matthes, "A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity," <u>J. Immunol. Methods</u> 15:61-69 (1988) ©Elsevier	
	A74	Decodts et al., "Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams," <u>Eur. J. Med. Chem. – Chim. Ther.</u> , 18(2):107-111 (1983)	
	A75	Dickson et al., "Tyrosine kinase receptor – nuclear protooncogene interactions in breast cancer," <u>Cancer Treatment Res.</u> 61:249-273 (1992) ©Kluwer Academic Publishers	
	A76	Fantl et al., "Distinct Phosphotyrosines on a Growth Factor Receptor Bind to Specific Molecules that Mediate Different Signaling Pathways," <u>Cell</u> 69:413-423 (1992) ©Cell Press	
	A77	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2-neu Gene product," <u>Cancer Research</u> 50:1550-1558 (1990) (mistakenly referred to as Fendley)	
	A78	Ferrara and Henzel, "Pituitary Fillicular Cells Secrete a Novel Heparin-Binding Growth Factor Specific for Vascular Endothelial Cells," <u>Biochemical and Biophysical Research Communications</u> 161:851-858 (1989) ©Academic Press, Inc.	

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 038602/1060	SERIAL NO.: 09/716,332
INFORMATION DISCLOSURE CITATION		APPLICANT: Namada SHENOY, et al.	
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)			
	A79		Fingl and Woodbury, "Chapter 1 - General Principles," in <u>The Pharmacological Basis of Therapeutics</u> 5 th edition, Goodman and Gilman editors, MacMillan Publishing Co., Inc., New York, pp. 1-46 (1975) ©MacMillan Publishing Co., Inc.
	A80		Floege et al., "Heparin suppresses mesangial cell proliferation and matrix expansion in experimental mesangioproliferative glomerulonephritis," <u>Kidney International</u> 43:369-380 (1993) ©International Society of Nephrology
	A81		Floege et al., "Factors involved in the regulation of mesangial cell proliferation <i>in vitro</i> and <i>in vivo</i> ," <u>Kidney International</u> 43:S47-S54 (1993) ©International Society of Nephrology
	A82		Folkman and Shing, "Angiogenesis," <u>J. Bio. Chem.</u> 267:10931-10934 (1992) ©The American Society for Biochemistry and Molecular Biology
	A83		Folkman, "Ch. 24. Angiogenesis," <u>Congress of Thrombosis and Haemostasis</u> (Verstraete et al., eds.) Leuven University Press, Leuven pp. 583-596 (1987)
	A84		Folkman, "Tumor Angiogenesis, Therapeutic Implications," <u>New England J. Medicine</u> 285:1182-1186 (1971)
	A85		Folkman, "What Is Evidence that Tumors Are Angiogenesis Dependent?" <u>Journal of National Cancer Institute</u> 82:4-6 (1990)
	A86		Gazit et al., "Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenmalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2-neu tyrosine kinases," <u>J. Med. Chem.</u> 34(6):1896-1907 (1991) ©American Chemical Society
	A87		Gennaro (editor), <u>Remington's Pharmaceutical Sciences</u> (1990) (TABLE OF CONTENTS ONLY)
	A88		Goldring and Goldring, "Cytokines and Cell Growth Control," <u>Critical Reviews in Eukaryotic Gene Expression</u> 1:301-326 (1991)
	A89		Graziani et al., "Hepatocyte Growth Factor/Scatter Factor Stimulates the Ras-Guanine Nucleotide Exchanger," <u>The Journal of Biological Chemistry</u> 268(13):9165-9168 (1993) ©American Society for Biochemistry and Molecular Biology
	A90		Hayler, et al., "Development of Large-Scale Synthesis of Ropinirole in the Pursuit of a Manufacturing Process," <u>Org. Process Res. Dev.</u> 2:(1):3-9 (1998) ©The American Chemical Society and Royal Society of Chemistry
	A91		Hirao et al., "Rhodium-catalyzed carbonylation of 2-alkynylanilines: syntheses of 1,3-dihydroindol-2-ones," <u>Tetrahedron Lett.</u> 36(35):6243-6246 (1995) ©Pergamon
	A92		Honegger et al., "Point Mutation at the ATP Binding Site of EGF Receptor Abolishes Protein-Tyrosine Kinase Activity and Alters Cellular Routing," <u>Cell</u> 51:199-209 (1987) ©Cell Press
	A93		Houck et al. "Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms," <u>J. Bio. Chem.</u> 267:26031-26037 (1992) ©American Society for Biochemistry and Molecular Biology, Inc.
	A94		Hu et al., "Interaction of Phosphatidylinositol 3-Kinase-Associated p85 with Epidermal Growth Factor and Platelet-Derived Growth Factor Receptors," <u>Molecular and Cellular Biology</u> 12(3):981-990 (1992) ©Am. Soc. Microbiol.
	A95		Jellinek et al., "Inhibition of Receptor Binding by High-Affinity RNA Ligands to Vascular Endothelial Growth Factor," <u>Biochemistry</u> 33:10450-10456 (1994) ©Am. Chemical Society
	A96		Kashishian and Cooper, "Phosphorylation Sites at the C-terminus of the Platelet-Derived Growth Factor Receptor Bind Phospholipase Cy1," <u>Molecular Biology of the Cell</u> 4:49-57 (1993) ©The American Society for Cell Biology
	A97		Kashishian et al., "Phosphorylation Sites in the PDGF receptor with Different Specificities for Binding GAP and P13 Kinase <i>in vivo</i> ," <u>The EMBO Journal</u> 11(4):1373-1382 (1992)

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 038602/1060	SERIAL NO. : 09/716,332
		APPLICANT: Narmada SHENOY, et al.	
INFORMATION DISCLOSURE CITATION			
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)			
	A98	Kato et al., "Simultaneous Determination of Amfenac Sodium and its Metabolite (7-Benzoyl-2-Oxindole) in Human Plasma by High-Performance Liquid Chromatography," <u>Journal of Chromatography</u> 616:67-71 (1993) ©Elsevier Science	
	A99	Kazlauskas et al., "The 64-kDa Protein That Associates with the Platelet-Derived Growth Factor Receptor β Subunit via Tyr-1009 Is The SH2-Containing Phosphotyrosine Phosphatase Syp," <u>Proc. Natl. Acad. Sci. USA</u> 90:6939-6942 (1993)	
	A100	Kendall and Thomas, "Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor," <u>Proc. Natl. Acad. Sci. USA</u> 90:10705-10709 (1993)	
	A101	Kikumoto, et al., "Reactions of oxindoles an disatin with nitrobenzyl chlorides. Formation of 2'-hydroxyspiro'2H-indole-2, 3' -3'H-indole!," <u>Tetrahedron</u> 22(10):3337-3343 (1966) ©Pergamon Press Ltd.	
	A102	Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppressed tumor growth in vivo," <u>Nature</u> 362-841-844 (1993)	
	A103	Kinsella et al., "Protein Kinase C Regulates Endothelial Cell Tube Formation on Basement Membrane Matrix, Matrigel," <u>Exp. Cell Research</u> 199:56-62 (1992) ©Academic Press Inc.	
	A104	Klagsburn and Soker, "VEGF-VPF: The Angiogenesis Factor Found?" <u>Current Biology</u> 3:699-702 (1993) ©Current Biology	
	A105	Koch et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins," <u>Science</u> 252:668-674 (1991)	
	A106	Komada and Kitamura, "The cell dissociation and motility triggered by scatter factor-hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor," <u>Oncogene</u> 8:2381-2390 (1993)	
	A107	Korc et al., "Overexpression of the Epidermal Growth Factor Receptor in Human Pancreatic Cancer is Associated with Concomitant increases in the Levels of Epidermal Growth Factor and Transforming Growth Factor Alpha," <u>J. Clin. Invest.</u> 90:1352-1360 (1992) ©The American Society for Clinical Investigation, Inc.	
	A108	Korzeniewski and Callewaert, "An Enzyme-Release Assay for Natural Cytotoxicity," <u>J. Immunol. Methods</u> 64:313-320 (1983) ©Elsevier Science Publishers	
	A109	Kumabe et al., "Amplification of α -platelet-derived growth factor receptor gene lacking an exon coding for a portion of the extracellular region in a primary brain tumor of glial origin," <u>Oncogene</u> 7:627-633 (1992)	
	A110	Lal et al., "Novel diuretic agents. Syntheses of substituted isatylidenes and 3-alkyl or 3-arylalkyl-2-oxindoles," <u>Indian J. Chem</u> 13(9):898-903 (1975)	
	A111	Lee and Donoghue, "Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction," <u>Journal of Cell Biology</u> 118:1057-1070 (1992) ©The Rockefeller University Press	
	A112	Levitzki et al., "Tyrosine kinase inhibition: An approach to drug development," <u>Science</u> 267:1782-1788 (1995)	
	A113	Maass et al., "Viral resistance to the thiazolo-iso-indolines, a new class of nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase," <u>Antimicrobial Agents and Chemotherapy</u> 37(12):2612-2617 (1993) ©American Society for Microbiology	
	A114	Macauley et al., "Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells," <u>Cancer Research</u> 50:2511-2517 (1990)	
	A115	Mariani et al., "Inhibition of angiogenesis by PCE 26806, a potent tyrosine kinase inhibitor," <u>Experimental Therapeutics - Proceedings of the American Association for Cancer Research</u> 35:381 at abstract no. 2268 (March 1994)	

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 038602/1060	SERIAL NO. : 09/716,332
INFORMATION DISCLOSURE CITATION		APPLICANT: Narmada SHENOY, et al.	
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)			
	A116	Millauer et al., "High Affinity VEGF Binding and Developmental Expression Suggest Flk-1 as a Major Regulator of Vasculogenesis and Angiogenesis," <u>Cell</u> 72:835-846 (1993) ©Cell press	
	A117	Mohammadi et al., "Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors," <u>Science</u> 276(5314):955-960 (1997) ©American Association for the Advancement of Science	
	A118	Moreto et al. "3,3-bis-(4-hydroxyphenyl)-7-methyl-2-indolinone (BHMI), the active metabolite of the laxative sulisatin" <u>Arzneimittel-Forschung Drug Research</u> 29(II):1561-1564 (1979)	
	A119	Moreto et al., "Study of the laxative properties of the disodium salt of the sulfuric diester of bis-(4-hydroxyphenyl)-7-methyl-2-indolinone(Dan-603) in the rat," <u>European Journal of Pharmacology</u> 36:221-226 (1976) ©North-Holland Publishing Company	
	A120	Morrison et al., "Signal Transduction from Membrane to Cytoplasm: Growth Factors and Membrane-Bound Oncogene Products Increases Raf-1 Phosphorylation and Associated Protein Kinase Activity," <u>Proc. Natl. Acad. Sci. USA</u> 85; 8855-8859 (1988)	
	A121	Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>J. Immunol. Methods</u> 65:55-63 (1983) ©Elsevier Publishers B.V.	
	A122	Nishimura et al., "Two Signaling Molecules Share a phosphotyrosine-Containing Binding Site in the Platelet-Derived Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 13:6889-6896 (1993)	
	A123	Plowman et al., "Receptor Tyrosine Kinases as Targets for Drug Intervention," <u>DN&P</u> 7(6):334-339 (1994)	
	A124	Quinn et al., "Fetal Liver Kinase 1 as a Receptor for Vascular Endothelial Growth Factor and is Selectively Expressed in Vascular Endothelium," <u>Proc. Natl. Acad. Sci. USA</u> 90:7533-7537 (1993)	
	A125	Rozakis-Adcock et al., "Association of the Shc and Grb2-Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases." <u>Nature</u> 360:689-692 (1992)	
	A126	Rygaard and Povlsen, "Heterotransplantation of a Human Malignant Tumor to 'Nude' Mice," <u>Acta path. microbiol. scand.</u> 77:758-760 (1969)	
	A127	Sainsbury, et al., "Electrochemical oxidation of aromatic ethers. Part 5. Further studies of the coupling reactions of alkoxylated aralkyl and aryl amides," <u>J. Chem. Soc.</u> , 1:108-114 (1979)	
	A128	Sandberg-Nordqvist et al., "Characterization of Insulin-Like Growth Factor 1 in Human Primary Brain Tumors," <u>Cancer Research</u> 53:2475-2478 (1993)	
	A129	Schlessinger and Ullrich, "Growth Factor Signalling by Receptor Tyrosine Kinases," <u>Neuron</u> 9:383-391 (1992) ©Cell Press	
	A130	Shibuya et al., "Nucleotide Sequence and Expression of a Novel Human Receptor-Type Tyrosine Kinase Gene (<i>flf</i>) closely related to the <i>fms</i> family", <u>Oncogene</u> 5:519-524 (1990)	
	A131	Singh et al., "Indolinone derivatives as potential antimicrobial agents," <u>Zentralbl. Mikrobiol.</u> 144:105-109 (1989) ©VEB Gustav Fischer Verlag Jena	
	A132	Singh et al., "Synthesis and Anticonvulsant Activity of New 1-Substituted 1'-Methyl-3-Chloro-2-Oxosprio (Azetidin-3', 4-Indol-2' Ones)," <u>Bollettino Chimico Farmaceutico</u> 133:76-79 (1994)	
	A133	Slamon et al., "Studies of the HER-2-neu Proto-oncogene in Human Breast and Ovarian Cancer," <u>Science</u> 244:707-712 (1989)	
	A134	Soldi et al., "Platelet-activating factor (PAF) induces the early tyrosine phosphorylation of focal adhesion kinase (p125 ^{FAX}) in human endothelial cells," <u>Oncogene</u> 13(3):515-525 (1996) ©Stockton Press	

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 038602/1060	SERIAL NO. : 09/716,332
INFORMATION DISCLOSURE CITATION		APPLICANT: Namada SHENOY, et al.	
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)			
	A135	Songyang et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences," <u>Cell</u> 72:767-778 (1993) ©Cell Press	
	A136	Songyang et al., "Specific Motifs Recognized by the SH2 Domains of Csk, 3BP2, fps-fes, GRB-2, HCP, SHC, Syk and Vav," <u>Molecular and Cellular Biology</u> 14:2777-2785 (1994) ©American Society for Microbiology	
	A137	Spada et al., "Small molecule inhibitors of tyrosine kinase activity," <u>Expert Opinion on Therapeutic Patents</u> 5(8):805-817 (1995) ©Ashley Publications	
	A138	Sun et al., "Synthesis and biological evaluations of 3-substituted indolin-2-ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases," <u>J. Med. Chem.</u> 41(14):2588-2603 (1998) ©The American Chemical Society	
	A139	Sun et al., "Design, Synthesis, and Evaluations of Substituted 3-[(3-or4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases," <u>J. Med. Chem.</u> , (42):5120-5130 (1999). ©American Chemical Society	
	A140	Superti-Furga et al., "A functional screen in yeast for regulators and antagonizers of heterologous protein tyrosine kinases," <u>Nature Biotech</u> 14:600-605 (1996)	
	A141	Superti-Furga et al., "Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src," <u>EMBO J.</u> 12:2625-2634 (1993) ©Oxford University Press	
	A142	Takano et al., "Inhibition of angiogenesis by a novel diaminoanthraquinone that inhibits protein kinase C," <u>Mol. Bio. Cell</u> 4:358A at abstract no. 2076 (1993)	
	A143	Thio et al., "Interconversion of 2-(2-aminophenyl)-3-piperolidinone and 3-(2-piperidylmethyl)-2-indolinone. Reversible N.dbr.N' transacylation" <u>J. Heterocycl. Chem.</u> , 8(3):479-482 (1971)	
	A144	Torp et al., "Expression of the Epidermal Growth Factor Receptor Gene in Human Brain Metastases," <u>AMPS</u> 100:713-719 (1992)	
	A145	Traxler, "Protein tyrosine kinase inhibitors in cancer treatment," <u>Expert Opinion on Therapeutic Patents</u> 7(6):571-588 (1997) ©Ashley Publications Ltd.	
	A146	Tsai et al., "The effect of 3,3-Di-Pyridyl-Methyl-1-Phenyl-2-indoline on the nerve Terminal Currents of Mouse Skeletal Muscles," <u>Neuropharmacology</u> 31(9):943-947 (1992) ©Pergamon Press	
	A147	Tuzi et al., "Expression of growth factor receptors in human brain tumours," <u>Br. J. Cancer</u> 63:227-233 (1990)	
	A148	Twamley-Stein et al., "The Src Family Tyrosine Kinases are Required for Platelet-Derived Growth Factor-Mediated Signal Transduction in NIH 3T3 Cells," <u>Proc. Natl. Acad. Sci.</u> , 90:7696-7700 (1993)	
	A149	Vaisman et al., "Characterization of the Receptors for Vascular Endothelial Growth Factor," <u>J. Biol. Chem.</u> 265:19461-19466 (1990) ©The American Society for Biochemistry and Molecular Biology	
	A150	Varma and Gupta, "Nucleophilic Reactions of 2-Methyl-3-(4'-carbomethoxyphenyl)-4-quinazolinones with 2-Indolinones," <u>J. Indian Chem. Soc.</u> 66:804-805 (1989) ©The Indian Chemical Society	
	A151	Voller et al., "Ch. 45 - Enzyme-Linked Immunosorbent Assay," in <u>Manual of Clinical Immunology</u> , 2 nd edition, Rose and Friedman editors, American Society of Microbiology, Washington, D.C., pp. 359-371 (1980)	
	A152	Walker, "The Reduction of Isoindogenides, Nitro Compounds, and Pyridines in a Series of 2-Indolinones," <u>J. Med. Chem.</u> 8(5):626-637 (1965)	

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: 038602/1060	SERIAL NO. : 09/716,332
INFORMATION DISCLOSURE CITATION		APPLICANT: Narmada SHENOY, et al.	
		FILING DATE: 11/21/2000	GROUP ART UNIT: 1615
	A153	Weidner et al. "Tumor Angiogenesis and Metastasis-Correlation in Invasive Breast Carcinoma," <u>New England Journal of Medicine</u> 324(1):1-8 (1991) ©Massachusetts Medical Society	
	A154	Wright et al., "Inhibition of Angiogenesis in Vitro and In Ovo With an Inhibitor of Cellular Protein Kinases, MDL 27032," <u>J. Cellular Physiology</u> 152:448-457 (1992)	
	A155	Zaman et al., "Tyrosine Kinase Activity of Purified Recombinant Cytoplasmic Domain of Platelet-Derived Growth Factor β -Receptor (β -PDGFR) and Discovery of a Novel Inhibitor of Receptor Tyrosine Kinases," <u>Biochemical Pharmacology</u> 57(1):57-64 (1999) ©Elsevier Science Inc.	
	A156	Zhang et al., "Microtubule Effects of Welvistatin, a Cyanobacterial Indolinone that Circumvents Multiple Drug Resistance," <u>Molecular Pharmacology</u> 49:228-294 (1996) ©The American Society for Pharmacology and Experimental Pharmaceutics	
EXAMINER		DATE CONSIDERED	
<p>* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.</p>			